3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Carcinoma, Hepatocellular
30
Neoplasms
19
Carcinoma, Renal Cell
16
Melanoma
10
Carcinoma, Non-Small-Cell Lung
10
Thyroid Neoplasms
9
Endometrial Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Liver Neoplasms
4
Carcinoma, Transitional Cell
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Lymphoma
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Carcinoma
3
Biliary Tract Neoplasms
3
Stomach Neoplasms
2
Solid Tumors
2
Osteosarcoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Glioma
2
Diabetes Mellitus, Insulin-Dependent, 12
2
Interventions
Gemcitabine
205
130-nm albumin-bound paclitaxel
84
Albumin-Bound Paclitaxel
57
pembrolizumab
43
Fluorouracil
41
Leucovorin
34
Oxaliplatin
33
Capecitabine
25
Nivolumab
22
Irinotecan
19
Bevacizumab
17
Paclitaxel
16
Cyclophosphamide
15
Cetuximab
15
Taxes
13
Erlotinib Hydrochloride
13
Drug Therapy
13
Carboplatin
12
irinotecan sucrosofate
11
Injections
10
Cisplatin
9
fludarabine
8
ALT-803
8
spartalizumab
7
olaparib
7
avelumab
7
Pemetrexed
7
Docetaxel
7
ruxolitinib
6
TH 302
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pancreatic Neoplasms
×
lenvatinib
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts